CRACR2A

Across TCGA pan-cancer cohorts, CRACR2A Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CRACR2A data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher CRACR2A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CRACR2A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, UCEC, and ESCA are the cancer types where CRACR2A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.500	0.963	<.001	36	view →
UCEC	DFS	Median	All	0.970	0.617	.007	28	view →
ESCA	OS	Median	II,III,IV	0.103	0.868	<.001	18	view →
OV	OS	Median	II,III,IV	0.435	0.692	.045	12	view →
SARC	OS	Median	All	0.178	0.730	.012	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CRACR2A–BRCA (OS)

Open the BRCA breakdown →